Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (October 2019)
23 slides from Genetic Signatures's investor presentation, Oct 28, 2019
Slide 1: Capital Raising Presentation
**DRAFT** Capital Raising Presentation 28 October 2019
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is propr
Slide 3: Executive summary
Executive summary • Three approved diagnostic tests for sale in over 30 countries utilising the company’s proprietary Genetic Signatures 3baseTM technology platform under the EasyScreenTM brand • Initial approved tests targeting pathogens in gastroenteritis, respiratory and antibiotic resistant (“GS
Slide 4: Executive summary
Executive summary • Moving from 3 to 5 registered products ‒ TGA registration to begin selling STI / Genital kits in Australia – targeting early 2020 ‒ TGA registration to begin selling Flavi / Alpha Kits in Australia – targeting early 2020 ‒ CE registration to begin selling STI / Genital kits in Eu
Slide 5: Significant growth in revenue and patients
Significant growth in revenue and patients Statutory revenue Cumulative patients tested using GSS kits (A$m) (‘000) 8 600 47% Core Revenue CAGR 6 400 4 200 2 - - FY15 FY16 FY17 FY18 FY19 FY15 FY16 FY17 FY18 FY19 Core Revenue R&D & Other Revenue Cumulative No. of Patients Tested • ~97% of FY19 core r
Slide 6: Product portfolio
Product portfolio 3 products selling in Australia and EU. Major new registrations and product launches imminent in US and EU Approved and commercializing Imminent approval and sales Global EasyScreen™ portfolio Test type Australia Europe North America market size1 CE-IVD Marked. Targeting FDA Enteri
Slide 7: The 3base technology behind our EasyScreen tests
The 3base™ technology behind our EasyScreenTM tests World-first, proprietary platform technology significantly simplifies genetic detection of microbial organisms in current urine, blood or stool tests 1 3baseTM platform technology converts Benefits for patients original 4-base microbial genome to 3-ba
Slide 8: Genetic Signatures revenue model
Genetic Signatures revenue model The 3baseTM kits are platform agnostic, although GSS hardware (GS1) is utilised by most customers Products Consumable revenue model - price per test ~65% gross margin GS1 Instrument EasyScreenTM Kit Customers are large pathology groups, hospitals or governmen
Slide 9: Executing a global strategy for commercialisation
Executing a global strategy for commercialisation GSS remains focused on growth in 3 major markets 2 Europe: On verge of significant revenue 3 tests CE-IVD Marked for sale in the EU Direct sales in UK, Germany Multiple distributors appointed or to be appointed for other countries Large pipel
Slide 10: Australia
Australia Commercialisation success in Australia. More growth via customers and new products Market Market Dynamics Dynamics • Market comprises private centralised labs, government and hospital networks • Private labs dominated by 3 large pathology groups (Sonic, Healius, Australian Clinical labs) -
Slide 11: Europe
Europe European Union and United Kingdom represents ~35% of global molecular diagnostics market1 Market Dynamics • Focus on selling direct in UK & Germany • 85% of testing in UK managed under NHS – mixed between Public Health England labs (7 centralised labs) and hospital trusts • Germany dominated
Slide 12: North America
North America North America is the largest market opportunity globally, accounting for an estimated 40% of molecular diagnostics revenue1 Market Dynamics • Est. 5.5m Enteric Protozoan tests p.a • Initial focus on largest 30 “high throughput” centralised labs • Smaller decentralised labs more accessi
Slide 13: M&A activity in the diagnostic sector
M&A activity in the diagnostic sector Strong strategic interest from large diagnostic companies in multiplex panels/assays such as GSS 3BaseTM technology. M&A activity within the sector expected to continue Date 2018 2018 2018 2017 2016 2011 Company Private (NASDAQ:CPHD) (Private) (Private) (NYSE:DG
Slide 14: Catalysts and newsflow
Catalysts and newsflow Expected to announce a significant amount of news flow and major catalysts by end of 2020 TGA registration to begin selling STI / Genital kits in Australia – targeting early 2020 TGA registration to begin selling Flavi / Alpha Kits in Australia – targeting early 2020 Ong
Slide 15: Offer Details
Offer Details
Slide 16: Offer details
Offer details Two Tranche Placement of ~A$35m to institutional and sophisticated investors and A$2m Share Purchase Plan Two Tranche Placement to institutions, sophisticated and professional investors to raise A$35.0 million via the issue of 35.7m shares: • Issue Price A$0.98 per share Placement • Tr
Slide 17: Use of funds
Use of funds Funds raised to rapidly grow global revenue and fully fund the Company through to profitability and breakeven • Expanding the global sales and support team towards 31 Increase sales and ‒ 24 new sales, marketing and support staff across EU, US $10.0m marketing team ‒ Staged rollout over
Slide 18: Offer timetable
Offer timetable Trading halt Thursday, 24 October 2019 Transaction announced & Company resumes trading Monday, 28 October 2019 Placement Tranche 1 Settlement of new shares Friday, 1 November 2019 Placement Tranche 1 Allotment of new shares Monday, 4 November 2019 SPP opens Monday, 4 November 2019 SP
Slide 19: Appendix
Appendix
Slide 20: Corporate summary
Corporate summary Genetic Signatures Limited (ASX: GSS) Financial information Share Price (23 October 2019) A$1.08 Share price (A$) Volume (m) 1.6 0.8 Shares on issue (pre) 104.1m1 Market capitalisation (pre) A$112.4m 1.2 0.6 Cash (pro-forma Sep-19 post offer) A$41.9m Debt Nil 0.8 0.4 Top shareholde
Slide 21: Board of Directors have a track record of success
Board of Directors have a track record of success Tony Radford Non executive Director • Significant sales experience • Co-Founder and CEO of Cellestis until acquired by Qiagen for c.US$400m • Proven track record of executing a sales strategy into Europe Phillip Isaacs Non executive director Michael
Slide 22: Powerful evidence of efficacy from clinical trials
Powerful evidence of efficacy from clinical trials Comparative studies confirm superior performance of Genetic Signatures’ technology Clinical trials demonstrate efficacy St Vincent’s Hospital Evaluation Study results Conventional Evaluation study conducted at Pathogen Methods* EasyScreen™ St. Vince
Slide 23: Contact us
Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media
Genetic Signatures — Investor Presentation (October 2019) on 6ix